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Abstract
Enhanced nuclear localization of nuclear factor κB (NF-κB) in prostate cancer (PCa) samples and constitutive NF-κB
signaling in a class of PCa cell lines with low androgen receptor (AR) expression (PC3 and DU-145) imply an important
role of the IκB kinase (IKK)/NF-κB system in PCa. However, most PCa and PCa cell lines depend on the activity of the
AR, and the role of NF-κB in these AR-expressing PCa remains unclear. Here, we demonstrate that inhibition of NF-κB
signaling by the IKK inhibitor BMS345541 reduced proliferation and increased apoptosis in AR-expressing PCa cell
lines. Furthermore, AR activity and target gene expression were distinctively reduced, whereas AR protein levels re-
mained unaltered on BMS345541 treatment. Similar effects were observed particularly after small interfering RNA
(siRNA)–mediated knockdown of IKK1, but not by siRNA-mediated suppression of IKK2. Moreover, IKK1 overexpres-
sion augmented 5α-dihydrotestosterone–induced nuclear AR translocation, whereas nuclear ARwas reduced by IKK1
knockdown or BMS345541. However, because IKK1 also enhances the activity of a chronically nuclear AR mutant,
modulation of the subcellular distribution seems not to be the only mechanism by which IKK1 enhances AR activity.
Finally, reduced in vivo AR phosphorylation after BMS345541 treatment and in vitro AR phosphorylation by IKK1 or
IKK2 imply that AR constitutes a novel IKK target. Taken together, our data identify IKK1 as a potentially target structure
for future therapeutic intervention in PCa.
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Introduction
Prostate cancer (PCa) is one of the most common malignancies and
one of the leading causes of cancer deaths in men in the United States
and in Europe. Therapy includes prostatectomy or radiation therapy in
case of organ-confined PCa and chemical or surgical castration causing
testosterone ablation in case of metastatic PCa. Most PCa cells re-
spond well to hormone ablation; however, after 18 to 36 months,
castration-resistant recurrence evolves eventually, which is unresponsive
to hormone ablation or chemotherapeutic intervention. Because of this
unresponsiveness, there is a growing need for novel therapeutic options
for the treatment of castration-resistant PCa (CRPCa).
The molecular target of castration therapy is the androgen receptor
(AR), a member of the superfamily of nuclear receptors, which is re-
sponsible for the development and function of the prostate epithelium.
On binding of its ligand—5α-dihydrotestosterone (DHT)—the AR is
released from a complex with heat shock proteins and translocates into
the nucleus where it induces a set of target genes necessary for cell
proliferation and survival. Therefore, castration-sensitive PCa cells
die on androgen deprivation. However, most of the CRPCa cells re-
main dependent on AR activity, which is maintained by alternative
mechanisms including AR gene amplifications, expression of specific
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AR splice variants, and AR mutations either causing a higher sensitivity
toward DHT or creating a broader ligand repertoire [1,2]. AR activa-
tion can also be achieved by site-specific phosphorylations, a mecha-
nism generally referred to as “outlaw pathway” of AR activation [3].
Besides this alternative AR activation, AR-independent pathways
have also been identified, which confer apoptosis resistance to PCa cells.
One of those pathways is nuclear factor κB (NF-κB) signaling, known
to regulate immune and inflammatory responses or developmental pro-
cesses. NF-κB is a dimer composed of nearly all combinations of the
NF-κB family members p65/RelA, RelB, c-Rel, NF-κB1/p50, or
NF-κB2/p52. Uninduced NF-κB dimers are restrained in the cyto-
plasm by complex formation with a member of the IκB family [4].
On stimulation, IκB proteins are phosphorylated by the multisubunit
IκB kinase (IKK) complex, subsequently ubiquitinated and degraded
through the proteasomal pathway [5]. Liberated NF-κB translocates
to the nucleus and induces the expression of a wide variety of NF-κB
target genes including BCL2, BCLXL, and BIRC5 as well as growth
factors like interleukin 6 [6,7]. The IKK complex consists of two
closely related kinases (IKK1/IKKα and IKK2/IKKβ) and an adaptor
protein (NEMO/IKKγ). More recently, the role of NF-κB in tumori-
genesis including PCa has been highlighted. For instance, elevated
NF-κB levels have been identified in primary PCa [8–13], and NF-κB
seems to be involved in the regulation of AR expression [14]. In addi-
tion, several AR target genes important for pathogenesis of PCa—like
PSA—are also regulated by NF-κB. By contrast, inactivation of IKK2
in prostate epithelial cells in a mouse model of chemically induced
CRPCa had an impact neither on the initiation and progression of
PCa nor on the formation of metastases [15]. CRPCa cell lines can be
subdivided in two groups, with PC3 and DU145 cells characterized by
constitutive IKK- and NF-κB activity and low or absent AR expression
(designated here as AR-negative CRPCa) and AR-positive VCaP, 22Rv1,
and LNCaP-SSR cells displaying low basal NF-κB activity. The growth
arrest of AR-negativeCRPCa cells after IKK blockage by pharmacological
inhibitors suggests that NF-κB is a main survival pathway that might
completely bypass the need for AR in these PCa cell lines [16]. By con-
trast, the role of NF-κB in AR-positive CRPCa is far less clear.
To define the role of IKK1 and IKK2 in AR-expressing PCa cells
more precisely, we analyzed proliferation and survival of a panel of
PCa cells by using either specific pharmacological IKK inhibitors or by
using small interfering RNA (siRNA)–mediated suppression of IKK1
and/or IKK2. Pharmacological IKK inhibition or siRNA-mediated
IKK suppression diminished proliferation and survival of PCa cell lines.
In addition, knockdown of IKK1 attenuated expression of AR target
genes. However, AR protein levels remained largely unchanged under
any of these conditions. In conclusion, we present here a novel regulatory
mechanism by which IKK1 controls the activity of AR.
Materials and Methods
Antibodies, Reagents, and Plasmids
The antibodies used were anti–phospho-serine (clone 1C8; Biomol
GmbH,Hamburg,Germany), anti-IKK1 (sc7218), anti-IKK1/2 (sc7607),
anti-NKX3.1 (15022), HDAC1 (sc7872), and ERK2 (sc15022) from
Santa Cruz Biotechnology (Santa Cruz, CA); anti-AR (441; Dako,
Glostrup, Denmark); anti-tubulin (B-5-1-2; Sigma-Aldrich, St Louis,
MO); and anti-IκBα (44D4, no. 4812; Cell Signaling Technology,
Inc, Danvers, MA). Cleaved caspase 3, cleaved caspase 9, and cleaved
poly (ADP-ribose) polymerase (PARP) antibodies were obtained from
the Cleaved Caspase Sampler Kit (no. 9929; Cell Signaling). Anti–
NF-κB2 antibody recognizing p100 and p52 are from Cell Signaling
(no. 4882). Wedelolactone, BMS345541, and DHT were purchased
from Sigma, and tumor necrosis factor α (TNFα) was purchased from
ImmunoTools (Friesoyte, Germany). Xpress-IKK1WT and Xpress-
IKK2WT have been described elsewhere [17]. The 3×κB-luc firefly, the
MMTVluc luciferase reporter, and the Renilla luciferase reporter have
been described previously [18]. Vectors for FLAG-His–tagged IKK1CA
or FLAG-tagged IKK1DNwere generated by inserting the complementary
DNA (cDNA) sequence in the pcDNA3 or pFLAG-CMV2 vectors.
Expression vectors encoding FLAG-tagged AR5, AR1, AR6, and AR7
were generated by insertion of the appropriate polymerase chain reaction
(PCR)–amplified cDNA sequence into the NotI and XbaI sites of the
pFLAG-CMV2 vector (Sigma).
Cell Culture and Transfection
Human PCa cell lines (LNCaP, VCaP, and 22Rv1) were obtained
from ATCC (Manassas, VA), and LNCaP-SSR cells were kindly pro-
vided by Dr Ralph Buttyan (Columbia University, New York, NY
[3]). The monkey fibroblastic COS7 cell line was kindly provided by
Dr Barabara Moepps (Institute of Pharmacology, University of Ulm,
Ulm, Germany). Unless otherwise indicated, cells were maintained at
37°C in 5% CO2 in RPMI medium supplemented with 10% fetal
bovine serum, 1% penicillin/streptomycin, and 1% glutamine. In all
experiments designated to establish the effect of hormone on AR, cells
were cultivated in medium with charcoal-stripped serum (CSS). Stock
solution of BMS345541 (Sigma) was prepared in dimethylsulfoxide,
and DHT (Sigma) was prepared in ethanol. For siRNA transfection of
LNCaP, Hi-Perfect Transfection Reagent (Qiagen, Hilden, Germany)
was used, and COS7 cells were transfected with Lipofectamine2000
according to the manufacturer’s protocol (Invitrogen, Life Technologies,
Ltd, Paisley, United Kingdom). The following siRNA for IKK1, IKK2,
or RelA was obtained by eurogentec (Seraing, Belgium): IKK1si1-
GGAAAGAAAUGGAAGAAAA-A55, IKK1si2-GGAUGUUGGU-
GGAAAGAU-A55, IKK2si1-GGUU AGGGCUUCUGAACU-
A55, IKK2si2-GGGAACAAGACCAGAGUU-U55, Si1RelA-C-
AACCAUGGCUUAAGGAA-A55, Si2RelA-GCAUUAACUUCUC-
UGGAA-A55, and control siRNA duplex negative control (5 nmol;
no. SR-CL000-005). The siRNA for human NF-κB2 p100/p52 was
from Qiagen (Hs_NFkB2_1).
Luciferase Reporter Assay
To determine the activity of NF-κB or AR, cells were transiently
transfected with either an AR reporter construct (MMTV-Luc) or an
NF-κB–dependent reporter (3×κB-luc) along with a plasmid encoding
a Renilla luciferase under the control of the human ubiquitin promoter
as the internal control. Attractene transfection reagent (Qiagen) was
used for transfection of LNCaP cells, Lipofectamine2000 (Invitrogen)
was used for transfection of COS7 cells, and CaPO4 method was used
for transfection of HEK 293 cells. In brief, 1 × 106 cells/well were
seeded. The next day, transfection was performed using 200 ng of a
Firefly luciferase plasmid along with 30 ng of the Renilla vector per
sample. Twenty-four hours after transfection, samples were treated with
20 nMDHT for at least 24 hours or 10 ng of TNFα for 4 hours (stim-
ulated) or the appropriate vehicle (unstimulated) as indicated. Pre-
treatment with BMS345541 or DMSO was started 2 hours before
stimulation. Luciferase activity was measured according to the Dual
Luciferase Reporter Assay System from Promega (Madison, WI).
Neoplasia Vol. 14, No. 3, 2012 IκB Kinases Control Androgen Receptor Activity Jain et al. 179
Firefly luciferase activity was normalized to the appropriate Renilla
luciferase values. The experiments were done in duplicates and were
repeated at least three times.
Cell Growth and Viability Assay
A total of 5 × 105 cells/well were seeded in 24-well plates and were
pretreated with inhibitor as indicated. After 18 to 24 hours, the me-
dium was exchanged, and cell proliferation was measured by adding
AlamarBlue dye (AbD Serotec, Kidlington, United Kingdom) for
1 to 4 hours. Fluorescence intensity (excitation = 560 nm, emission =
590 nm) was measured with a SPECTRAMaxGeminiEM fluorometer
(Molecular Devices, Sunnyvale, CA) using the SOFTMAXPro soft-
ware. All measurements were done in triplicates and were repeated at
least three times. Statistical analysis was performed as described here.
To determine survival of LNCaP and LNCaP-SSR cells, cells were cul-
tivated in RPMI + CSS for 2 hours before BMS345541 treatment for
another 18 hours under standard conditions either without or with an
additional treatment with DHT. Cell numbers were counted using
a Neubauer chamber (Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen, Germany). Experiment was performed with triplicates,
and statistical analysis was done as described later.
Immunoprecipitation and Immunoblot Analysis
Whole-cell extracts were prepared by using TNT buffer (20 mMTris
pH 8.0, 200 mMNaCl, 1% Triton X-100, 1 mMDTT, 50 mMNaF,
50 mM β-glycerophosphate, 50 μM leupeptin, 1 mM phenylmethylsul-
fonyl fluoride [PMSF]), and isolation of cytoplasmic and nuclear pro-
teins was achieved by subsequent incubation of the cells in buffer A
(10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 0.5 mM PMSF) and buffer C (20 mM HEPES
pH 7.9, 0.4 MKCl, 1 mMEDTA, 1 mMEGTA, 1 mMDTT, includ-
ing protease inhibitors [COMPLETE Protease Inhibitor; Roche Applied
Sciences, Mannheim, Germany]). Immunoprecipitation and immuno-
blot analysis procedures were performed as described previously [17].
In brief, 250 to 500 μg of protein extracts was mixed with 1 μg of
antibody/sample, and samples were incubated overnight at 4°C with
agitation. Afterwards, 10 μl of 50% protein G slurry was added, and
samples were further incubated for 1 hour. Subsequently, precipitates
were washed in TNT buffer and subjected to immunoblot analysis.
For the immunoblot analysis, either the immunopurified protein com-
plexes or 50 to 100 μg of a protein extract was separated on SDS-PAGE
and then transferred to nitrocellulose membranes (Schleicher & Schuell,
Whatman, Dassel, Germany) using standard protocols. The membrane
was blocked with 5%milk powder in TBS–Tween-20 before incubating
with the primary antibody (1:1000 inTBS–Tween-20) and subsequently
washed and incubated in a TBS–Tween-20 solution containing horse-
radish peroxidase–conjugated secondary antibody (1:5000). The detec-
tion was performed using ECL substrates (Pierce, Thermo Scientific,
Rockford, IL). For the densitometric quantification, the scanned images
were analyzed using the ImageJ software (National Institutes of Health,
Bethesda, MD).
Immunoprecipitation and Kinase Assay
HEK 293 cells were transfected with appropriate plasmid using
CaPO4 method. Forty-eight hours after transfection, cells were lysed
with TNT buffer, and lysates were subjected to anti-FLAG IP for
2 hours at 4°C. Immunoprecipitates were washed thrice with TNT and
once with KAB (20mMHEPES pH 7.6, 2 mMEGTA, 10 mMMgCl2,
1 mM DTT, 0.1% Triton X-100, 20 mM β-glycerophosphate, 5 mM
NaF, 1 mM PMSF). For kinase reaction, samples were mixed as
indicated along with 10 μCi of 32P-labeled γATP per sample in 30 μl
of KAB and incubated for 30 minutes at 30°C with agitation. Sub-
sequently, immunoprecipitates were washed once with PBS and were
resolved by SDS-PAGE, transferred to nitrocellulose membrane, and
visualized by autoradiography. Successful immunoprecipitation was
determined with immunoblot analysis.
RNA Extraction and Quantitative Real-time PCR Analysis
Quantitative real-time PCR was performed by using the iCycler
PCR instrument (Bio-Rad Laboratories, Hercules, CA). Total
RNA was prepared using RNeasy protect kit from Qiagen according
to the manufacturer’s protocol. One microgram of total RNA was
used to generate cDNA using First-Strand Synthesis kit (Invitrogen).
Quantitative PCR was performed using 0.1 μl of cDNA reaction mix
in the IQSYBR Green SuperMix (Bio-Rad). PCR was carried out as
follows: after an initial 3-minute preincubation step at 95°C, 40 ampli-
fication cycles were run (95°C for 30 seconds, 55°C for 30 seconds, and
72°C for 15 seconds). Quantification of gene regulation was performed
by the ΔΔCpmethod. Results are presented relative to the expression of
the housekeeping gene β-ACTIN. Sequences of primers used for quan-
titative PCR are available on request. The primers for BIM were
obtained from RealTimePrimers (LLC, Elkins Park, PA).
Statistical Analysis
All the results are expressed as the mean ± SD of at least three in-
dependent data sets. Student’s t test was used to compare the mean of
two groups and to calculate P value. P < .05 was considered significant.
Gel Shift Analysis
For the gel shift analysis (electrophoretic mobility shift asay), 5 μg
of nuclear proteins or whole-cell extracts (DignamC extracts) from
untreated or stimulated cells was incubated on ice for 20 minutes in
a reaction containing 0.3 ng of 32P-labeled κB-specific or Oct-specific
oligonucleotide, 1 μg pdI:dC and 3 μl of a binding buffer. The samples
were separated on a native 5% polyacryl amide gel, and the gel was
dried and subjected to autoradiography.
Results
Pharmacological Inhibition of IκB Kinases Impairs Cell
Growth and Attenuates AR Signaling in PCa Cell Lines
The controversial picture regarding the role of NF-κB in PCa
prompted us to explore the function of NF-κB in AR-expressing
PCa cell lines. Proliferation of PCa cell lines (LNCaP-SSR, VCaP,
22Rv1, and LNCaP) treated with the IKK inhibitor BMS345541
was significantly attenuated in a dose-dependent manner when com-
pared with untreated PCa cells (Figure 1A). Similar effects were seen
with IKK inhibitors wedelolactone and Bay 117082 (data not shown).
Further analysis of the BMS345541 effect in androgen-dependent
LNCaP and androgen-independent LNCaP-SSR cells revealed a sig-
nificant reduction in survival of both cell lines (Figure 1B), which
was most likely due to an increased apoptosis because levels of cleaved
PARP and cleaved caspases 3 and 9 were elevated (Figure 1, C and D).
As expected, levels of cleaved PARP were highest in samples cultivated
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in absence of androgens (Figure 1C , lanes 2 and 3). Morphologic
changes induced by BMS345541 treatment of LNCaP cells (Figure 1E)
further supported the notion that IKK inhibition caused increased
apoptosis. A reduced NF-κB–dependent expression of AR might be
responsible for the negative BMS345541 effect on PCa proliferation
and survival. However, BMS345541 treatment had no gross effect
on AR expression in LNCaP and LNCaP-SSR cells (Figure 1, C and
D). Furthermore, AR protein levels remained stable on BMS345541
treatment also in CRPCa cell lines 22Rv1 and VCaP (Figure W1),
whereas the expression of the AR target NKX3.1 showed a significant
reduction in LNCaP cells. Collectively, these data suggest that pharma-
cological inhibition of IKKs is deleterious for AR-positive PCa cell lines.
The reduced expression of the AR target genes PSA, PME, NKX3.1,
and TMPRSS2 and NF-κB target gene BIM (which was included
as internal NF-κB control) in BMS345541-treated 22Rv1, LNCaP,
and LNCaP-SSR cells (Figure 2A) further underscored these findings.
BMS345541 impaired NF-κB signaling in LNCaP cells in a dose-
dependent manner as monitored by the TNFα-induced IκBα degrada-
tion (Figure 2B). Again, AR protein levels remained unaffected by
BMS345541 treatment (Figure 2B, middle panel). BMS345541 pre-
treatment also caused a significant reduction of the TNFα-induced
NF-κB activity by luciferase reporter assays (Figure 2C , upper part). Im-
portantly, also a distinct attenuation of the AR activity on BMS345541
treatment was observed with either LNCaP or 22Rv1 cells (Figure 2C ,
lower part). Together, these results demonstrate a negative effect of
IKK inhibition on NF-κB and AR activity, whereas AR protein levels
remain stable.
Knockdown of IKK1 or IKK2 Affects PCa Cell Growth
To exclude potential off-target effects of BMS345541, we compared
cell proliferation in IKK1 siRNA– as well as IKK2 siRNA–transfected
LNCaP cells (Figure 3A). siRNA-mediated suppression of IKK1 or
IKK2 caused a distinct reduction of viable cell numbers (Figure 3A).
Again, knockdown of IKK1 had no obvious effect on AR protein levels
(Figure 3B, lanes 1-4 ), whereas a reduced AR expression after IKK2
suppression was occasionally detectable (Figure 3B, lanes 5-8). Analysis
of TNFα-induced NF-κB DNA binding activity by EMSA showed a
more pronounced decrease after IKK1 suppression then by knockdown
of IKK2 (Figure 3C , upper panel). Similarly, knockdown of IKK1 or
IKK1 + IKK2 caused a considerable reduction in the expression of
the AR target genes NKX3.1, PSA, and TMPRSS2 in VCaP or LNCaP
cells, although the degree of inhibition showed some variations (Fig-
ure 4, A and B). By contrast, suppression of IKK2 alone had only a
moderate effect on the expression of the AR target genes, whereas it
is essential for the basal expression of the NF-κB target BIM (Fig-
ure 4D). To further analyze the potential functional divergence
between IKK1 and IKK2 regarding their impact on AR activity, either
IKK1CA or IKK2WT was overexpressed in LNCaP cells (in control ex-
periments, IKK2WT was highly active, whereas IKK1CA was required
for full IKK1 activity [data not shown]) in conjunction with either a
NF-κB–dependent reporter (Figure 5A) or an AR-dependent reporter
(Figure 5B). As expected, NF-κB activity was moderately increased by
IKK1CA andmore pronounced by IKK2WT overexpression (Figure 5A).
However, only overexpression of IKK1CA, but not of IKK2WT, led to
a distinct increase in AR-dependent activity (Figure 5B).
Figure 1. Growth inhibition of androgen-dependent and androgen-independent PCa cells by BMS345541. (A) Cells were either left untreated
or treated with BMS345541 (8 μM; 14 μM) for 24 hours, and cell proliferation was measured by reduction of AlamarBlue dye (bars depict
mean ± SD, **P < .0001, *P < .001, compared with vehicle control). (B) Twenty-four hours after exposure to BMS345541 (0, 10, and
20 μM) of LNCaP and LNCaP-SSR cells, viable cell numbers were determined. Graph indicates mean ± SD. LNCaP (C) and LNCaP-SSR
(D) cells were treated with BMS345541 for 24 and 48 hours. Cells were left unstimulated (−) or stimulated with 20 nM DHT (+), and
whole-cell extracts were subjected to immunoblot analysis with the indicated antibodies. (E) LNCaP cells were either left untreated
(Co) or were treated with indicated concentrations of BMS345541 for 24 hours. Cell morphology is depicted as bright field images (original
magnification, ×20).
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To further dissect the positive IKK1 effect on AR, reporter gene
analysis was performed in COS7 cells ectopically expressing either
full-length AR (AR5) or a constitutive active AR mutant harboring a
truncated carboxy-terminus (AR7). Again, addition of IKK1CA
augmented the activity of AR5 as well as of AR7 (Figure 5C ). Fur-
thermore, AR activity in transiently transfected HEK 293 cells was
reduced in the absence of IKK1, whereas IKK2 knockdown either
had no effect or even led to a slight increase in AR activity in unstimu-
lated cells (Figure 5D, upper part). Accordingly, AR5 protein levels
remained stable, whereas IKK1 and IKK2 were efficiently reduced
by the corresponding siRNAs as measured by immunoblot analysis
(Figure 5D, lower part). A similar effect of siRNA-mediated IKK1 or
IKK2 suppression was observed when the constitutive active AR7 dele-
tionmutantwas used. TheAR7mutant lacks the carboxy-terminal ligand
binding domain and is therefore constitutively located in the nucleus.
Again, AR7 activity was reduced after IKK1 knockdown was and mod-
erately increased after IKK2 suppression (Figure W2, right panel ),
whereas AR7 protein levels remain stable in IKK siRNA–transfected
cells (Figure W2, left panel ). Collectively, these results imply that espe-
cially IKK1 is capable of increasing the activity of full-length AR or a
constitutively active AR version.
IKK1 Augments the Hormone-Induced Nuclear
Translocation of AR
To further characterize the positive IKK1 effect on AR activity,
subcellular localization of AR was analyzed in LNCaP cells. Without
BMS345541, cytosolic AR levels decreased in hormone-stimulated
cells, whereas nuclear AR levels increased (Figure 6A, lanes 1 and
2 and lanes 7 and 8). Pretreatment with 20 μM BMS345541 reduced
nuclear AR, whereas the nuclear and cytoplasmic p52 levels remained
unaffected (Figure 6A, lanes 3-6 and lanes 9-12; a quantification of
the nuclear AR seen in lanes 8 and 12 is given at the right panel ) and
stabilized cytosolic AR levels. Consistently, siRNA-mediated IKK1 sup-
pression in LNCaP cells led to a moderately reduced DHT-induced
nuclear translocation of the AR (Figure 6B, compare lanes 2 and 4 ).
To further delineate the effect on hormone-induced nuclear locali-
zation of the AR, COS7 cells were transfected with AR5 either alone
or in combination with IKK1CA or IKK2WT as indicated (Figure 7A).
Subsequently, the cells were left untreated or were stimulated with
DHT before the analysis of the subcellular distribution of the AR.
Again, IKK1CA coexpression alone was not sufficient to increase nuclear
AR levels in unstimulated cells (Figure 7A, lanes 3, 5, and 7). However,
in stimulated cells, nuclear AR was distinctively increased by IKK1CA,
Figure 2. BMS345541 inhibits transcriptional activity of AR and NF-κB. (A) LNCaP, LNCaP-SSR, and 22Rv1 cells were either left untreated
(Co) or treated with 8 μM BMS345541 for 24 hours (BMS). Quantitative PCR analysis of AR, AR target genes (PSA, PME, NKX3.1, and
TMPRSS2), and NF-κB target gene (BIM) was performed. Normalized readings were plotted relative to Co of each gene. Bar depicts mean
± SD. *P < .001, **P < .0001. (B) LNCaP cells were pretreated for 4 hours with BMS345541 (0, 20, and 40 μM) followed by TNFα stimula-
tion for 20 minutes. Resulting whole-cell extracts were subjected to immunoblot analysis for the indicated proteins. (C) LNCaP cells were
transiently transfected with a 3×κB-luc (upper part) or with the MMTVluc (lower part) and treated with BMS345541 (8 μM) for 24 hours.
Cells transfected with 3×κB-luc were additionally stimulated with TNFα (+TNF) or were not further stimulated (−TNF) for 3 more hours.
Subsequently, dual luciferase analysis was performed with all samples. Bars depict mean ± SD of normalized luciferase reading relative to
untreated samples.
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Figure 3. Effect of siRNA-mediated suppression of IKK1 and/or IKK2. (A) LNCaP cells were transfected with the indicated IKK siRNA. Four
days after transfection, viable cell numbers were determined and plotted as mean ± SD. (B) Efficiency of knockdown corresponding to
A was checked by immunoblot analysis. The same membrane was reprobed with antibodies recognizing AR and ERK2. (C) LNCaP cells
were transfected with IKK1 and/or IKK2 siRNA, as indicated. After 72 hours, cells either were left untreated (−TNFα) or were stimulated
with 10 ng/ml TNFα for 20 minutes. EMSA for NF-κB or Oct probes was performed with nuclear extract of these cells (upper panel).
Corresponding cytoplasmic extracts were used for immunoblot analysis with indicated antibodies (lower panel).
Figure 4. IKK1 siRNA attenuates the expression of AR target genes. VCaP (A) and LNCaP cells (B) were transfected with IKK1 and/or IKK2
siRNA. Forty-eight hours after transfection, cells were either left untreated or treated with 20 nM DHT (+) for an additional 24 hours. Tran-
script levels of AR, PSA, NKX3.1, and TMPRSS2 were analyzed with real-time PCR. Histogram depicts fold change in transcript levels after
siRNA transfection relative to Co-siRNA–transfected samples. (C) IKK1, IKK2, and AR protein levels in corresponding LNCaP samples were
determined with immunoblot analysis. (D) Similar quantitative PCR analysis of BIM transcript levels after knockdown of IKK1 and/or IKK2
siRNA in LNCaP cells.
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whereas coexpression of IKK2WT reduced hormone-induced nuclear
AR (Figure 7A, left part, lanes 9-12). Accordingly, coexpression of a
dominant-negative IKK1 mutant (IKK1DN) attenuated DHT-induced
nuclear translocation of the AR in COS7 cells (Figure 7B, lanes 4 and
8), suggesting that enzymatic activity of IKK1 is required for increased
nuclear AR. Studies by Nadiminty et al. [19] revealed a cytokine-
induced and IKK1-dependent mobilization of NF-κB2/p52:AR
heterodimers as a novel hormone-independent mechanism for AR
activation. However, neither BMS345541 treatment (Figure 6A) nor
IKK1 suppression (Figure 4C) had a gross effect on either the nuclear
p52 levels or the processing of the NF-κB2/p100 precursor, sug-
gesting that the observed IKK1 effect could not only be dependent
on NF-κB/p52.
To analyze a potential effect of IKK1 on the DNA binding of the
AR, full-length AR5 was expressed in COS7 cells alone or in com-
bination with IKK1WT, IKK2WT, or IKK1CA. Nuclear proteins from
untreated (Figure 7C , lanes 1-5) or from DHT-stimulated cells
(Figure 7C , lanes 6-10) were used for EMSA experiments with either
an androgen response element (Figure 7C , left part, upper panel ) or a
κB-specific oligonucleotide (Figure 7C , left part, lower panel ). As ex-
pected, IKK2WT augmented basal NF-κB activity in COS7 cells,
whereas IKK1CA or IKK1WT increased NF-κB activity only moderately
(Figure 7C , lanes 1-5). By contrast, neither IKK1CA/IKK1WT nor
IKK2WT caused an increased basal DNA binding of the AR
(Figure 7C , lanes 1-6 ). However, IKK1CA led to a distinct increase
in the hormone-induced DNA binding of the AR, whereas IKK2WT
Figure 5. Effects of IKK1 and IKK2 on AR activity. (A, B) LNCaP cells were transfected with IKK1CA or IKK2WT (0, 100, and 300 ng), along
with either 3×κB-luc (A) or MMTVluc (B). After 24 hours, dual luciferase analysis was performed. Bars in histogram represent mean ± SD
of normalized relative light unit (RLU) relative to IKK-untransfected samples. *P≤ .03, **P≤ .001, compared with control always. (C) COS7
cells were transfected with MMTVluc and Ubi-Renilla and with increasing amounts of IKK1CA along with either full-length AR (AR5) or con-
stitutive active AR (AR7). Luciferase values were determined 24 hours after transfection. The mean values ± SD of the normalized RLU
are depicted. (D) 293 cells were cotransfected with IKK siRNA along with MMTVluc and Ubi-Renilla. Twenty-four hours after transfection,
cells were stimulated with 20 nM DHT (+DHT) or left untreated (−DHT) for another 24 hours. Mean ± SD of normalized RLU value of
respective transfection is depicted (upper part). Knockdown efficiency was controlled by immunoblot analysis with the corresponding
samples (lower part).
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reduced AR binding (Figure 7C , lanes 7-10). Immunoblot analysis
revealed a moderate increase in nuclear levels of the hormone in-
duced AR by IKK1CA (Figure 7C , lower part, lanes 7 and 8), whereas
IKK2WT caused slightly reduced nuclear AR levels (lanes 8 and 9).
Moreover, corresponding cytoplasmic extracts also showed a moderate
decrease in AR levels and additional slower-migrating AR isoforms
in cells with IKK2WT coexpression. Although the basis for the addi-
tional slower-migrating AR isoforms remains unclear, it is tempting
to speculate that these might resemble AR molecules with specific
posttranslational modifications.
The AR Is an IKK Target In Vitro
To analyze whether the AR constitutes an IKK substrate, we first
determined whether IKK inhibition by BMS345541 treatment af-
fects the phosphorylation status of the AR. Hence, LNCaP cells were
pretreated with 5 or 10 μM BMS345541 before cell lysis. Phosphory-
lation of the AR was determined with anti-AR immunoprecipitation
followed by immunoblot analysis with anti–phospho-Ser antibodies.
Indeed, IKK inhibition decreased AR phosphorylation, suggesting that
AR might resemble an IKK target protein (Figure 8A, compare lanes 1
and 3). To determine whether AR is phosphorylated by IKK1 or
IKK2 in vitro, we expressed FLAG-tagged full-length AR (AR5) or
a panel of FLAG-tagged deletion mutants of the AR (AR1, AR6,
AR7; see Figure 8B, lower part, for a schematic representation) in
HEK 293 cells. The FLAG-tagged AR proteins were immunopurified
and subjected to an in vitro kinase assay with likewise immunopurified
FLAG-tagged IKK1 or IKK2 proteins. Interestingly, full-length AR
protein as well as all AR deletion mutants were efficiently phosphory-
lated by IKK2 and less pronounced by IKK1 (Figure 8B, upper part).
Furthermore, the highest phosphorylation was observed with the
amino-terminal deletion mutants AR1 (aa 1-360) and AR6 (aa 1-535;
Figure 8B, upper part, lanes 2 and 3 and lanes 5 and 6 ). Furthermore,
an interaction of AR either with IKK1 (Figure W3A) or with IKK2
(Figure W3B) was observed in interaction studies with ectopically
expressed proteins. These data show that the AR is a target of IKK1
and IKK2 and imply a phosphorylation-dependent regulation of AR
by the IKKs.
Discussion
A prominent role of NF-κB in the initiation or progression of PCa
has been proposed previously. This notion is supported by the chronic
IKK and NF-κB activity observed in a group of androgen-independent
PCa cell lines (PC3 or DU145) [9,16] and the elevated NF-κB activa-
tion reported for primary PCa cases [8,11,20]. For instance, Gasparian
et al. [9] reported nuclear RelA in approximately 25% of the cells.
Figure 6. Effect of IKK inhibition and IKK1 knockdown on nuclear translocation of the AR. (A) LNCaP cells were cultivated in Dulbecco
modified Eagle medium (DMEM) + charcoal-stripped fetal calf serum (CS-FCS) for 2 hours before pretreatment with BMS345541 (0, 10,
and 20 μM) for an additional 1 hour. Subsequently, cells were either left untreated (−) or treated (+) with DHT for 1 hour, and nuclear and
cytoplasmic proteins were subjected to immunoblot analysis using anti-AR, anti-HDAC1, and anti-tubulin antibodies. The subcellular
distribution of p52 was determined with immunoblot analysis in a similar experiment (lower part). (B) LNCaP cells were transiently trans-
fected with either control siRNA (Co) or with IKK1si2 siRNA (IKK1). After 48 hours, the cells were transferred to DMEM + CS-FCS for
3 hours followed by treatment with either vehicle (DMSO, −) or with DHT (5 nM, +) for an additional hour. Subsequently, nuclear and
cytoplasmic proteins were extracted and subjected to immunoblot analyses with antibodies for the indicated proteins. A quantification
of the cytoplasmic and the nuclear AR protein levels in DHT-stimulated cells (lanes 2 and 4) is given in the right part.
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Therefore, a constitutive NF-κB activity was proposed to generally
replace the AR in PCa, and the androgen-independent PCa cell lines
PC3 or DU145 were assumed to be model systems for CRPCa. How-
ever, most CRPCa cells depend on a functional AR, whereas PC3 and
DU145 cells are devoid of measurable AR expression levels. Thus, PC3
and DU145 cells might represent only a subgroup of CRPCa. To
analyze the importance of the NF-κB/IKK system in AR-positive
PCa, we determined the effect of specific IKK inhibitors on growth
and survival of the androgen-dependent PCa cell line LNCaP, and the
androgen-independent PCa cell lines 22Rv1, VCaP, and LNCaP-SSR.
Irrespective of their AR status or androgen sensitiveness, the growth of
all PCa cell lines tested was impaired by the IKK inhibitors BMS345541
and wedelolactone (Figure 1; data not shown), suggesting a prominent
role of IKKs in AR-expressing PCa cells. Onemolecular mechanismmay
be the regulation of AR expression byNF-κB [14]. Indeed, a reduced AR
activity (Figure 3B) and expression of different AR target genes (Figure 2)
by BMS345541 treatment was observed. However, although a reduced
AR expression might also contribute to the overall picture, it seems not
to be the major mechanism because protein levels of the AR were found
to be unaffected inBMS345541-treated LNCaP, VCaP, and 22Rv1 cells
(Figures 1, C and D, and W1).
BMS345541 is known to impair both IKK1 and IKK2 [21]. Be-
cause NF-κB–dependent and NF-κB–independent functions were
reported for both IKKs [4], the altered AR functions on BMS345541
treatment might be due to different mechanisms. Although both IKK
isoforms are inhibited by BMS345541, our biochemical analyses
Figure 7. Differential effects of IKK1 or IKK2 coexpression on nuclear expression and DNA binding of the AR. (A) COS7 cells expressing
ectopic AR5 alone or in combination with FLAG-IKK1CA or FLAG-IKK2WT as indicated were either left untreated (−) or stimulated with
20 nM DHT (+) for 1 hour. The resulting nuclear and cytoplasmic extracts were subjected to immunoblot analysis. This experiment was
repeated twice, and a quantification of selected samples of all three experiments is given in the right part. (B) COS7 cells, transiently
transfected with FLAG-AR5 alone or with FLAG-IKK1CA or HA-IKK1DN, were incubated in DMEM + CSS before stimulation with DHT for
1 hour. Nuclear and cytoplasmic extracts were subjected to immunoblot analysis with the indicated antibodies. This experiment was
repeated twice, and a quantification of selected samples of all three experiments is given in the right part. (C) COS7 were transiently
transfected with FLAG-AR5, FLAG-IKK1CA, FLAG-IKK2WT, and FLAG-IKK1WT as indicated. Subsequently, cells were treated either with
solvent or with DHT (+) for 1 hour. Nuclear extracts were subjected to EMSA experiments using NF-κB (left part, lower panel) or AR
(left part, upper panel) specific oligonucleotides. In addition, immunoblot analysis with the indicated antibodies was performed with the
cytoplasmic (C) and nuclear (N) proteins (right part).
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suggest that IKK1 is the predominant positive regulator of AR activity,
whereas IKK2 seems to have mainly a negative impact on AR activity.
For instance, the suppression of IKK1 attenuates the expression of AR
target genes (TMPRSS2, PSA, or NKX3.1) in LNCaP and VCaP cells
(Figure 4, A and B), and only IKK1CA coexpression, but not the addi-
tion of IKK2, augmented the AR activity in reporter gene assays (Fig-
ure 5B). Different mechanisms might account for the positive IKK1
effect on AR. One of these mechanisms is the nuclear translocation of
the AR. This notion is supported by 1) the reduced hormone-induced
nuclear translocation of AR by BMS345541 treatment (Figure 6A), 2)
the attenuated nuclear translocation after siRNA-mediated IKK1
knockdown (Figure 6B), 3) the increased nuclear translocation of
full-length AR in hormone-induced COS7 cells on IKK1CA co-
expression (Figure 7A), and 4) the reduced nuclear expression of AR
on IKK1DN coexpression (Figure 7B). A previously reported IKK1-
dependent mobilization of NF-κB2/p52:AR heterodimers [19,22]
might contribute to the increased nuclear AR expression. However, this
seems not to be the exclusive mechanism because neither BMS345541
treatment nor IKK1 knockdown affected NF-κB2 expression or p100
processing (Figures 4C and 6A). Furthermore, the increased activity
of the already constitutive nuclear AR mutant AR7 by coexpression of
IKK1CA (Figure 5C) and its reduced activity in cells with IKK1 knock-
down (Figure W2) suggest that nuclear translocation is not the only
level modulated by IKK1. Another level might be an increased DNA
binding activity of the AR (Figure 7C).
In contrast to IKK1, IKK2 seems to have divergent roles. IKK2
might have a positive effect on AR activity indirectly by controlling
basal AR expression (Figure 3B), also evident by BIM expression (Fig-
ure 4D). The basis for this positive IKK2 effect on AR is not completely
clear. Although a moderate increase in AR expression by RelA was
observed previously [14], we were unable to detect changes in AR pro-
tein and mRNA levels after knockdown of either RelA or p100/p52
(Figure W4), suggesting that different IKK2-dependent NF-κB dimers
might regulate AR expression in a redundant fashion. Conversely, IKK2
coexpression attenuated the nuclear translocation of AR (Figure 7A,
lanes 9-12), and finally, IKK2 reduced the DNA-binding activity of
AR (Figure 7C , compare lanes 7 + 9), suggesting a negative effect of
IKK2 on AR protein functions. Consistently, knockdown of IKK2
Figure 8. The AR is an IKK target in vitro. (A) LNCaP cells were exposed to BMS345541 (0, 5, and 10 μM). After 48 hours, AR was
immunoprecipitated (IP), and anti–phospho-serine, AR, and ERK2 immunoblot analysis was performed. Histogram depicts densitometry
of anti–phospho-serine signals relative to control. (B) 293 cells expressing AR5, AR deletion mutants, IKK1, or IKK2 were lysed, and
anti-FLAG immunoprecipitation was performed. Kinase reaction was performed with AR proteins alone or with either IKK1 or IKK2
and analyzed with autoradiography. Arrows indicate the position of AR variants. A schematic representation of AR variants is given
in the lower part. (C) Model depicting the mechanism by which the IKK proteins control the activity of the AR: DHT binding induced
nuclear localization, ARE binding, and target gene induction by AR. IKK1 phosphorylates AR in the nucleus and/or cytoplasm causing
an increased nuclear localization of AR (1). IKK1 additionally affects transcriptional activity of AR independent of its nuclear localization
possibly by altered DNA binding ability or Cofactor interaction (2). IKK2 attenuates ligand-dependent nuclear localization of AR most
likely by phosphorylating AR at alternative sites (3). Conversely, IKK2 regulates AR expression (4). In addition, IKK2 seems to affect
cytoplasmic AR by modifying AR after translation (5).
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augmented the basal activity of both the full-length AR (Figure 5D, upper
panel, left part) and the constitutive active AR7 mutant (Figure W2),
further supporting this notion. In addition, IKK2 coexpression caused
the formation of slower-migrating AR isoforms in the cytoplasm (Fig-
ure 7C , left part). Because the AR is a target for several posttranslational
modifications like phosphorylation, ubiquitination, or SUMOylation
[23–26], it is very likely that these additional AR isoforms are caused
by such posttranslational modifications. Experiments are underway to
characterize these posttranslational AR modifications. The various levels
at which IKK1 and IKK2 affect the AR is summarized in a model in
Figure 8C .
Divergent roles of IKK1 and IKK2 for the initiation and progression
of PCa have been reported previously. Suppression of IKK1 by siRNA,
for instance, delayed the appearance of castration resistant PCa in the
murine myc-CaP allograft model of PCa [15], whereas deletion of
IKK2 had no effect. However, nuclear localization of IKK1 was evident
for this process as well as for the negative regulation of MASPIN ex-
pression [15,27]. A potential mechanism underlying the positive IKK1
effect on AR activity might include the IKK1-mediated phosphoryla-
tion of this transcription factor [28,29] illustrated by the IKK-mediated
phosphorylation of the amino-terminal DNA binding domain of the
AR (Figure 8B). The activity or the stability of other non-IκB targets
like RelA or p53 is influenced by IKK-mediated phosphorylation [5].
Furthermore, phosphorylation of the estrogen receptor at Ser118 was
found to be impaired by the IKK inhibitor Bay 117082 [30]. There-
fore, an IKK-mediated phosphorylation of the AR might be another
example of non-IκB IKK targets. In this line, it is important to men-
tion that the AR is targeted by several kinases like the MAPK, protein
kinase C, protein kinase A, or glycogen synthase kinase 3. These
phosphorylations affect the protein-protein interactions of the AR
(including cofactor interaction), the stability of the AR, the nuclear
localization, or the DNA binding activity [29,31,32]. One prominent
example is the glycogen synthase kinase 3–mediated phosphorylation
of the AR, which increases the nuclear localization and, in turn,
the activity and stability of the AR. Interestingly, most of the known
phospho-acceptor sites in AR are located in its amino-terminus [23,28]
similar to the IKK-mediated AR phosphorylation (Figure 8B). There-
fore, an IKK1-mediated phosphorylation of the amino-terminus of
the AR, which positively affects the activity of this nuclear receptor,
is consistent with the previously reported functions of AR phosphory-
lations. However, several important questions need to be answered in
future studies. For instance, the identity of the serine residues serving
as target sites for IKK1 and/or IKK2 need to be defined. In this line,
it is necessary to define the stimuli causing the activation of IKK1. In-
terleukin 6– or lymphotoxin β–induced and phosphorylated signal
transducer and activator of transcription 3–mediated activation of
IKK1 has been reported to play a crucial role in the progression toward
castration-independent growth of PCa by enhancing p100 process-
ing and mobilization of p52:AR heterodimers into the nucleus in a
hormone-independent fashion [19,33,34]. Although no gross change
in p100 or p52 protein levels was observed on BMS345541 treatment
or IKK1 knockdown (Figures 4C and 6A), IKK1-mediated AR phos-
phorylation might act in conjunction with a likewise IKK1-dependent
p100 processing to establish the overall positive IKK1 effect on AR
activity. Moreover, the nature of the IKK2-dependent additional post-
translational AR modification and its potential role in the regulation
of the AR needs to be determined. However, taken together, our data
suggest that IKK1-specific pharmacological inhibitors might represent
promising tools for therapeutic intervention in PCa.
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Figure W1. Analysis of AR protein levels in BMS345541-treated
PCa cell lines. LNCaP, 22Rv1, and VCaP cells were treated with
BMS345541 (0,1, 2, 4, 8, and 14 μM) for 4 hours, and whole-cell
extracts were subjected to anti-AR, anti-Nkx3.1, and anti-ERK2
immunoblot analyses as indicated. Note: 22Rv1 cells express an
additional shorter AR splice variant.
Figure W2. IKKs affect the activity of a nuclear AR mutant. HEK 293 cells were cotransfected with indicated IKK siRNA and MMTVluc/
Ubi-Renilla along with the ligand-independent nuclear AR7 mutant. Graph depicts mean ± SD of normalized RLU value of the respective
transfection. Knockdown efficiency of IKK1 and IKK2 and expression levels of AR7 was controlled by immunoblot analysis with the
corresponding samples.
Figure W3. The AR forms protein complexes with IKK1 or IKK2. (A)
IKK1 was ectopically expressed in HEK 293 cells either with or with-
out full-length AR (AR5) or constitutive active AR (AR7). Forty-eight
hours after transfection, whole-cell extracts were prepared, and
10% of lysate was subjected to control immunoblot analyses (preIP,
lower part), and 90% of lysate was subjected to anti-AR immunopre-
cipitation (IP). IP samples were analyzed with immunoblot for AR
and IKK1 (IP, upper part). (B) 293 cells were transfected with expres-
sion vectors encoding FLAG-tagged IKK2 (IKK2FL) with or without
full-length AR (AR). Forty-eight hours after transfection, whole-cell
extracts were prepared, and 10% of lysate was subjected to control
immunoblot analyses (preIP, lower part) and 90% of lysate was
subjected to anti-FLAG immunoprecipitation (IP). IP samples were
analyzed with immunoblot for AR and IKK2 (IP, upper part).
Figure W4. Knockdown of individual NF-κB subunits does not affect AR transcripts. LNCaP cells were transfected with siRNA for RelA or
p100/p52. Cells were cultured in normal serum–supplemented medium for 72 hours before the analysis of AR mRNA levels by real-time
PCR. Histogram depicts the fold change in transcript levels after siRNA transfection relative to control siRNA–transfected samples. RelA,
p100, p52, and AR protein levels of corresponding samples were determined with immunoblot analysis.
